HIPRA is a biotech pharmaceutical company headquartered in Amer, Catalonia, Spain focused on prevention for animal and human health, with a product base of vaccines and diagnostic services.[1]
HIPRA has an international presence in 40 countries with its own subsidiaries, 3 R&D centres and production plants located in Europe (Spain) and America (Brazil).
In addition, its international distribution network maintains open distribution channels with more than 100 countries, covering all 5 continents.[2]
Since 2020, the company has been developing a vaccine against COVID-19.[3]
HIPRA got founded in 1971, in a small laboratory in Madrid.[4] The name HIPRA comes from the surnames of its former creators: Hidalgo and Prada.
In 1991 HIPRA had a workforce of 100 people and a turnover of 10 million euros, it was an important year in HIPRA's history, with a new management team, and a redefined company expansion policy.[5]
In the year 2000, the company began internationalization, beginning the implementation of its own subsidiaries around the world. Currently HIPRA has commercial subsidiaries in 40 countries. It also has 3 research centers and 6 production plants located in Europe and America.
In 2009 HIPRA began to focus on prevention; therefore, it stopped investing in pharmacological products.
In 2021 the new Human Health division was created by HIPRA to create new products.[6] The same year, GoodGut was acquired by HIPRA, a biotechnological start-up dedicated to the research and development of diagnostic tests for digestive diseases.[7]
HIPRA has developed more than 100 vaccines for different animal species, both production and companion animals, against a wide variety of biological targets. In addition to its Amer plant, the company has another plant in Brazil, in the Porto Alegre conurbation. It also has a university research centre in the United States.[8]
HIPRA's animal health products include vaccines, vaccination devices,[9] integrated traceability services and diagnostic kits.